Pulmovant is a clinical-stage biotechnology company developing innovative therapies for patients suffering from pulmonary diseases. Pulmovant’s first program, mosliciguat is designed to provide an effective, once-daily, inhaled treatment option for patients with pulmonary hypertension (PH). Mosliciguat is a novel, potential first-in-class, sGC activator with a differentiated mechanism that may have broad applicability across the PH spectrum.
Company Details
- Employees
- 34
- Address
- 303 Wyman St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.pulmovant.com/
- HQ
- Waltham, MA
Pulmovant Questions
Pulmovant's website is https://www.pulmovant.com/
Pulmovant's LinkedIn profile is https://www.linkedin.com/company/pulmovant
Pulmovant has
34 employees.
View email and phone details for 34
employees at Pulmovant.
Pulmovant's industry is
Biotechnology Research
Pulmovant's top competitors are
Apogee Therapeutics,
Kinevant Sciences,
Gossamer Bio,
Hemavant Sciences,
Aruvant,
Roivant,
Beam Therapeutics,
Priovant Therapeutics,
Immunovant,
Sumitomo Pharma America, Inc..
Pulmovant's categories are Biotechnology Research
